Skip to main content

Table 4 Patients receiving prothombin complex concentrate dose in compliance with recommendations of the French National Health Authority (Haute Autorité de Santé)

From: Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice

Initial international normalized ratio

2-2.5

(n= 57)

2.5-3

(n= 53)

3-3.5

(n= 49)

> 3.5

(n= 249)

Unknown

(n= 71)

Patients with infused dose < expected dose

1 (1.8)

6 (11.3)

15 (30.6)

182 (73.1)

24 (34.7)

Patients with infused dose = expected dose

9 (15.8)

22 (41.5)

20 (40.8)

67 (26.9)

47 (65.3)

Patients with infused dose > expected dose

47 (82.5)

25 (47.2)

14 (28.6)

0

0

  1. Results are expressed as number (percentage). Results are presented in patients with documented prothombin complex concentrate dose and initial international normalized ratio (INR) of at least 2 or unknown INR (n = 479).
Back to article page

Critical Care

ISSN: 1364-8535